Tornai David, Antal-Szalmas Peter, Tornai Tamas, Papp Maria, Tornai Istvan, Sipeki Nora, Janka Tamas, Balogh Boglarka, Vitalis Zsuzsanna
Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, 98 Nagyerdei krt., 4032, Debrecen, Hungary.
Kálmán Laki Doctoral School of Biomedical and Clinical Sciences, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
BMC Gastroenterol. 2021 Mar 2;21(1):94. doi: 10.1186/s12876-021-01669-w.
Both iron overload and iron deficient anemia can associate with cirrhosis. At the same time, inflammation might be continuously present in cirrhotic patients due to bacterial translocation and patients' susceptibility to infections. Ferritin is a sensitive and widely available marker of iron homeostasis, in addition it acts as an acute phase protein. Therefore, we evaluated the prognostic potential of serum ferritin in the long-term follow-up of cirrhotic outpatients.
A cohort of 244 cirrhotic outpatients was recruited and followed for 2 years. We measured their serum ferritin levels in our routine laboratory unit at enrolment and investigated its association with clinical outcomes.
Ferritin serum level was higher in males and older patients than in females (median: 152.6 vs. 75 μg/L, p < 0.001) or younger individuals (median: 142.9 vs. 67.9 μg/L, p = 0.002). Patients who previously survived variceal bleeding had lower ferritin levels (median: 43.1 vs. 146.6 μg/L, p < 0.001). In multivariate regression models, including laboratory and clinical factors, lower (< 40 μg/L) ferritin concentration was associated with the development of decompensated clinical stage in patients with previously compensated cirrhosis (sHR: 3.762, CI 1.616-8.760, p = 0.002), while higher (> 310 μg/L) circulating ferritin levels were associated with increased risks of bacterial infections in decompensated patients (sHR: 2.335, CI 1.193-4.568, p = 0.013) and mortality in the whole population (HR: 2.143, CI 1.174-3.910, p = 0.013).
We demonstrated usefulness of serum ferritin as a prognostic biomarker in cirrhosis, pointing out that both low and high concentrations need attention in these patients.
铁过载和缺铁性贫血均可能与肝硬化相关。同时,由于细菌移位以及患者对感染的易感性,炎症可能持续存在于肝硬化患者中。铁蛋白是铁稳态的一个敏感且广泛可用的标志物,此外它还作为一种急性期蛋白发挥作用。因此,我们评估了血清铁蛋白在肝硬化门诊患者长期随访中的预后潜力。
招募了一组244例肝硬化门诊患者,并对其进行了2年的随访。我们在入组时在常规实验室检测了他们的血清铁蛋白水平,并研究了其与临床结局的关联。
男性和老年患者的血清铁蛋白水平高于女性(中位数:152.6对75μg/L,p<0.001)或年轻个体(中位数:142.9对67.9μg/L,p=0.002)。既往有静脉曲张出血存活的患者铁蛋白水平较低(中位数:43.1对146.6μg/L,p<0.001)。在多变量回归模型中,纳入实验室和临床因素后,较低(<40μg/L)的铁蛋白浓度与既往代偿期肝硬化患者失代偿临床阶段的发生相关(标准化危险比:3.762,置信区间1.616 - 8.760,p=0.002),而较高(>310μg/L)的循环铁蛋白水平与失代偿患者细菌感染风险增加(标准化危险比:2.335,置信区间1.193 - 4.568,p=0.013)以及整个人群的死亡率增加相关(危险比:2.143,置信区间1.174 - 3.910,p=0.013)。
我们证明了血清铁蛋白作为肝硬化预后生物标志物的有用性,指出在这些患者中低浓度和高浓度铁蛋白均需关注。